{'fraction_non_alphanumeric': 0.04087208349270532, 'fraction_numerical': 0.016392546855363094, 'mean_word_length': 5.458009880028229, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging

Neuroendocrine neoplasms (NENs) are heterogeneous tumours with a common phenotype descended from the diffuse endocrine system. NENs are found nearly anywhere in the body but the most frequent location is the gastrointestinal tract. Gastrointestinal neuroendocrine neoplasms (GI-NENs) are rather uncommon, representing around 2% of all gastrointestinal tumours and 20–30% of all primary neoplasms of the small bowel. GI-NENs have various clinical manifestations due to the different substances they can produce; some of these tumours appear to be associated with familial syndromes, such as multiple endocrine neoplasm and neurofibromatosis type 1. The current WHO classification (2019) divides NENs into three major categories: well-differentiated NENs, poorly differentiated NENs, and mixed neuroendocrine-non-neuroendocrine neoplasms. The diagnosis, localization, and staging of GI-NENs include morphology and functional imaging, above all contrast-enhanced computed tomography (CECT), and in the field of nuclear medicine imaging, a key role is played by 68Ga-labelled-somatostatin analogues (68Ga-DOTA-peptides) positron emission tomography/computed tomography (PET/TC). In this review of recent literature, we described the objectives of morphological/functional imaging and potential future possibilities of prognostic imaging in the assessment of GI-NENs.


Introduction
Neuroendocrine neoplasms (NENs) are epithelial tumours that originate from the diffuse endocrine system cells. They share the expression of neuroendocrine markers (such as chromogranin A and synaptophysin) and can secrete multiple different aminoacids and polypeptides, which may result in several clinical syndromes [1]. The neuroendocrine system is distributed over several organs, so NENs have many different denominations [2]: medullary carcinoma in thyroid, carcinoid, large-cell neuroendocrine carcinoma and smallcell carcinoma in lung and thymus, paraganglioma in extrasurrenal paraganglia, pheochromocytoma in adrenals and Merkel cell carcinoma in the skin.
NENs are most frequent in gastrointestinal tract (about 70% of cases), followed by lung (around 25% of cases) and pancreas [3].
Gastrointestinal neuroendocrine neoplasms (GI-NENs) are rather uncommon, representing around 2% of all gastrointestinal tumours and 20-30% of all primary neoplasms of the small bowel [4,5]; they derive from enterocromaffin cells and are predominantly situated in the distal ileum [5,6].
Clinically, we can classify NENs into non-functioning and functioning tumours. The functioning tumours secrete substances that cause appreciable clinical symptoms, whereas the non-functioning neoplasms do not secrete any substance or the substance produced is inactive. NENs can be sporadic, be the only manifestation of a disease, or be part of a multiple endocrine neoplasm (MEN), together with other endocrine tumours [2]. In addition to MEN, GI-NENs can associate with other genetic syndromes such as Von Hippel-Lindau and Neurofibromatosis type 1 [3]. At the time of diagnosis, only 15% of patients have the typical carcinoid syndrome, characterized by facial flushing, diarrhoea, or bronchospasm due to serotonin hypersecretion; otherwise, patients who present non-specific symptoms, such as weight loss, bleeding, and abdominal pain, are asymptomatic [7][8][9]. Carcinoid syndrome can facilitate NENs's detection, despite many patients have advanced disease at diagnosis with distant metastases, mainly to the regional lymph nodes, liver, and bone [10][11][12]. Just over half of GI-NENs are diagnosed in the emergency setting with symptoms of gastrointestinal obstruction or bleeding [4].
In this review of recent literature, we aimed to evaluate the principal imaging features of GI-NENs to stratify patients into more defined clinical categories and to provide insights for precision medicine and appropriate treatments.

Morphological imaging
Radiologic imaging plays a key role in the diagnosis, staging, and follow-up of GI-NENs [4,14,15].
The main techniques involved in abdominal radiology are ultrasound (US), contrast-enhanced computed tomography (CECT), and magnetic resonance imaging (MRI); this type of imaging is used to determine the size and location of primary tumour, as well as for staging and for evaluation of potential treatment choices.
Abdominal ultrasound is a radiation-free imaging examination [16,17], but has a restricted role in the evaluation of gastrointestinal disease [18,19]. Depending on location, sensitivity of abdominal US in revealing GI-NENs has variable percentage values (around 12-28%) [20]. Walczyk et al. reported how GI-NEN appears as a mass arising from the walls of gastrointestinal tract, and it may occur as hypoechoic lesions with a hyperechoic rim or as hyperechoic lesions ( Fig. 1) [20,21]. However, US examination is limited by operator dependence, it is not a panoramic method and visualization is confined to the field of investigation [20].
To date, the most widely used imaging modality for the detection of GI-NENs is undoubtedly CECT [4,[22][23][24][25][26], which allows diagnosis, staging, pre-and post-treatment evaluation and follow-up of these neoplasms (Fig. 2). A standard CECT protocol can be employed for both diagnosis and follow-up; patients can be scanned in the supine position with craniocaudal apnoea scans and should undergo non-contrast and contrast-enhanced CT scanning. Iodinated contrast medium can be injected into the antecubital vein at a flow rate of 3-4 mL/s using an automatic injector, immediately followed by a saline flush (40-50 mL). Contrastenhanced biphasic images can be achieved during the arterial phase (30-35 s after injection onset) and the portal venous phase (70-75 s after injection onset) [27]. Enterographic computed tomography is a hybrid procedure that combines the techniques of intubation-infusion of small bowel imaging with those of conventional abdominal CT [28][29][30]. CT enterography has been shown to be useful in depicting small bowel parietal abnormalities and to be superior to conventional CT in this field; it has already been described by Kamaoui et al. that the sensitivity of CT enteroclysis in identifying small bowel NENs is 100% with a specificity of 96% [31]. At the time of diagnosis, approximately, half of patients with GI-NENs manifest advanced disease with metastases, most frequently localized to loco-regional lymph node stations, liver parenchyma, or bone [12][13][14][15] (Figs. 3,  4). The imaging appearance of NENs is widely variable, and it depends on localization, size, and margins, relationship to  the bowel wall and the presence of intralesional alterations (haemorrhage, calcifications, necrosis, cystic degeneration, and ulceration) that modify its densitometric homogeneity and contrastographic pattern [4,11]. After contrast medium injection, these gastrointestinal neoplasms may appear as a hypervascular nodular swelling originating from the intestinal wall or as a localized thickening of the wall [11] (Fig. 4). The boundary between the tumour and the adjacent tissue may be well or poorly defined; indeed, these lesions may have smooth, regular margins or jagged and irregular edges [4,11].
They are typically solid, but may have intralesional necrosis or cystic degeneration and, frequently, coarse or thin calcifications. Among the extra-intestinal manifestations of GI-NENs, the most typical is mesenteric metastasis associated with a desmoplastic reaction; this metastasis presents as a solid mass in the mesenteric fat adjacent to the primary neoplasm, associated with soft tissue rays, that radiate from the central mass to the small bowel. These extra-intestinal signs can cause complications such as kinking or angulation of bowel [4]. Other manifestations detectable at CECT are invasion of adjacent organs, omental/peritoneal involvement, metastases (lymphnode and liver), and ascites [12,13] (Fig. 5). Many studies have demonstrated the correlation between CT features and pathological classification, revealing statistically significant differences between well-differentiated NENs and poorly differentiated NENs in terms of lesion size, growth, intra-or extra-intestinal involvement, zone of intralesional alterations, mesenteric fat infiltration and metastases; indeed, the finding on CT examination of lesions larger than 4 cm with necrotic or cystic areas in context, circumferential growth with transmural invasion, extra-intestinal involvement with mesenteric fat infiltration and lymphadenopathies, is more common in poorly differentiated NENs [4].
Magnetic resonance imaging has an excellent soft tissue contrast [32][33][34] and, as abdominal US, it is a radiation-free imaging examination. The standard protocol for the evaluation of GI-NENs provides T1 and T2-weighted sequences, diffusion-weighted imaging (DWI), and dynamic contrastenhanced imaging after administration of contrast medium [35][36][37]. Usually, GI-NENs appear hypointense on T1 and hyperintense on T2-weighted images, demonstrate a contrast enhancement pattern similar to that of CECT [8], and show diffusion restriction on DWI [38] (Fig. 6). Nevertheless, MRI is less used for the evaluation of patients with suspected GI-NENs because it is a time-consuming analysis and for its susceptibility to movement artefacts.

Functional imaging of GI-NENs
Nuclear medicine study aids morphological imaging in the assessment of GI-NENs and that is allowed since common feature of most GI-NENs is the expression of somatostatin receptors (SSTRs) [39,40]. This characteristic is exploited by nuclear medicine imaging to detect sites of disease, using radio-labelled SST analogues (SSA). For functional imaging of GI-NENs, we use somatostatin receptor scintigraphy with 111 Indium-pentetreotide ( 111 In-Octreoscan), 111 Indium-pentetreotide (Octreoscan®) uses a radiolabelled somatostatin analogues that detects neuroendocrine neoplasms by binding to characteristic somatostatin receptors displayed on the surface of GI-NEN cells [41][42][43]. Following administration of 111 Indium-pentetreotide, wholebody scintigraphy is performed to diagnose, localize, and stage GI-NENs, but at the same time, it is important to remember that a significant subgroup of NENs is somatostatin receptor-negative. For GI-NENs, these scans have associated positive predictive values of 84.6% and negative predictive values of 50% [44,45].
Krausz et al. in their study reported how Octreoscan® accuracy in diagnosis of liver metastases was 82%, this percentage is linked to several factors intrinsic to the method such as the low spatial resolution (usually around 1 cm) and long acquisition timings; moreover, reduced Somatostatin receptor scintigraphy detection of known lesions may be associated with a lower density or absence of receptors [46].
A fundamental and innovative role in the identification of GI-NENs has been the use of 68Ga-labelled somatostatin analogues ( 68 Ga-DOTA-peptides) in positron emission tomography/computed tomography (PET/CT). Respect to Somatostatin receptor scintigraphy, 68 Ga-DOTA-peptides have a higher sensitivity and spatial resolution and provide the possibility of image quantification [47][48][49].
Recently, a lot of study have reported the diagnostic superiority of 68 Ga-DOTA-peptides over other diagnostic investigation in the detection of GI-NENs [50,51]. In particular, within of GI-NENs, 68 Gallium-DOTA-peptides have been shown to have a better detection rate compared with CECT of primary tumour (89% vs 25%) and carcinomatosis (88% vs 75%), a higher detection rate than conventional Somatostatin receptor scintigraphy (95.1% vs 45.3%), and a lower radiation dose due to the shorter length of study (2 h); this method has also high sensitivity (93.5%) in the detection of liver metastasis from GI-NENs. [52,53]. With the increased use of multiple radionuclide ligands, it is hoped that 68 Ga-DOTA-peptides will have a crucial role in the future in assigning class risk stratification and data for personalized treatment in patients with 8,9).
A new hybrid chelator ( 68 Ga-DATA-peptides) has recently been introduced. This one has the advantage of radio-labelling at room temperature in lesser time compared to 68 Ga-DOTA-peptides, with high radiochemical yield in a istant kit-type fashion. In particular, although 68 Ga-DOTA-peptides are nowadays the current standard for imaging of GI-NENs, recent studies have shown that 68 Ga-DATA-peptides' elegant labelling profile is associated with diagnostic accuracy comparable to 68 Gallium-DOTA-peptides [54,55]. 18 FFluorodeoxyglucose-positron emission tomography allows to evaluate the metabolic activity of GI-NENs by studying the radio-labelled glucose metabolism. This method uses the increased glycolytic activity and increased expression of glucose transporters by tumour cells to identify these neoplasms compared to non-pathological tissue. [56]. A lot of study reported how 18 F-FDG-PET has a limited role in the assessment of well-differentiated GI-NENs, but can be valuable for poorly differentiated GI-NENs [57,58]. This is due to the fact that well-differentiated GI-NENs are more likely to express somatostatin receptors with high density, while poorly differentiated GI-NENs may display a lower density of somatostatin receptors but are more metabolically active, thus making them better visualized by 18 F-FDG-PET. Additionally, Panagiotidis et al. in their study reported how the presence of increased glucose in GI-NENs highlights an increased propensity for invasion and metastasis, and how 18 F-FDG-PET accordingly has higher sensitivity in delineating disease extend, mainly in aggressive and high-grade tumours [58].

Prognostic imaging of GI-NENs
In the new era of precision medicine, radiomics is an emerging domain of research aiming to extract mineable highdimensional data from diagnostic images (mainly from CECT, PET or MRI) [59]. The notion underlying the process is that both morphological and functional images contain qualitative and quantitative information, which may reflect the underlying pathophysiology of a tissue. Radiomics' analyses can be performed in tumour regions, metastatic lesions, as well as in normal tissues [60]. The search method uses the following steps: acquisition of CT/RM/PET images of diagnostic quality, segmentation of neoplasm with definition of ROI of interest, extraction of radiomics features from the whole segmented volume or alternatively of some ROIs by appropriate software. The extracted features are generally divided into four categories: descriptive like shape, size, location; first-order statistics such as intensity histograms that relate pixel intensity (x-axis) to the number of pixels (y-axis) with analysis of mean, median, standard deviation, quartiles, kurtosis, skewness; second-order statistics concerns the analysis of the textures obtained, also known as "Haralick descriptors"; higher-order statistics represent repetitive and non-repetitive patterns extracted by Kernel transforms. Finally, statistical analysis and "data mining" are carried out to obtain diagnostic, predictive, and prognostic models by machine learning [61]. Several recent studies have begun to test the additional possibilities of quantitative imaging in many areas of abdominal oncology [62][63][64][65][66][67][68][69], but to the best of our knowledge, there are no known articles on this subject for GI-NENs. It would be interesting in the near future to extend quantitative imaging studies to this type of neoplasms, since the use of radiomics and texture analysis could be promising also in GI-NENs for more accurate diagnosis and differentiation, tumour risk stratification, management and assessment of treatment response.

Conclusions
In conclusion, morphological imaging plays a fundamental role in diagnosis, staging, and post-treatment follow-up of GI-NENs; functional imaging allows not only to detect the neoplasm but also may be useful in predicting differentiation grade of GI-NENs. One of the possible further developments for GI-NENs could be the evaluation of quantitative imaging with texture analysis, radiomic and radiogenomic features that may be useful in the prognostic assessment of these tumours. In fact, in GI-NENs, the main clinical question concerns the need of the patient risk stratification. Therefore, together with the overall clinical profiles (morphological and functional imaging, symptoms and individual risk for evolving disease), prognostic imaging could potentially Fig. 9 Axial pre-contrast image (a), arterial phase (b) and portal venous phase (c) contrastenhanced CECT show hypervascular liver metastasis (white arrows) of NEC that becomes almost isodense on the portal venous phase except for central areas of necrosis. At 68 Ga-PET TC imaging (d) the liver lesion shows Ga uptake be a decisional factor to stratify patients into more defined clinical categories for precision medicine and appropriate treatment.
Funding Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

Declarations
Conflict of interest The authors declare that they have no conflict of interest related to the publication of this article.

Ethical standards
The manuscript does not contain clinical studies or patient data.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.